Partial
Partially Aligned
Patient Risk:
Moderate
Summary
Several mechanistic and interaction-related statements about beetroot juice are not supported or addressed in the provided LIPITOR labeling. Statin-associated muscle injury guidance is directionally consistent with the label’s skeletal muscle warning, but other safety statements (low blood pressure/dehydration/renal disease) are not supported by the supplied label text.
Category Scores
Accurate Statements
Atorvastatin is metabolized by cytochrome P450 3A4.
Section 7.1: “LIPITOR is metabolized by cytochrome P450 3A4.”
Grapefruit contains components that inhibit CYP 3A4 and can increase atorvastatin plasma concentrations, especially with excessive grapefruit juice consumption (>1.2 liters/day).
Section 7.2: “Contains one or more components that inhibit CYP 3A4 and can increase plasma concentrations of atorvastatin, especially with excessive grapefruit juice consumption (>1.2 liters per day).”
Statins can rarely cause muscle injury; muscle pain or weakness can be a sign of statin-related muscle injury.
Section 5.1: “occasionally causes myopathy” and “Rare cases of rhabdomyolysis…”; also includes guidance to temporarily withhold/discontinue with acute, serious condition suggestive of myopathy.
If there is an acute, serious condition suggestive of myopathy or risk factor predisposing to rhabdomyolysis-related renal failure, LIPITOR therapy should be temporarily withheld or discontinued.
Section 5.1: “LIPITOR therapy should be temporarily withheld or discontinued in any patient with an acute, serious condition suggestive of a myopathy…”
Unsupported Statements
There is no specific, well-known food-drug interaction that says you cannot drink beetroot juice while taking atorvastatin.
The provided labeling does not address beetroot juice or state that no interaction exists.
Beetroot juice mainly acts as a source of dietary nitrates.
Not addressed in the provided LIPITOR prescribing information.
Dietary nitrates can affect blood pressure and related blood flow pathways.
Not addressed in the provided LIPITOR prescribing information.
Standard dietary beetroot juice is not known for inhibiting or inducing CYP3A4 in a way that would reliably raise or lower atorvastatin levels.
The provided labeling does not discuss beetroot juice metabolism or CYP3A4 effects.
Grapefruit-style enzyme inhibition is not the usual issue with beetroot juice.
Not addressed in the provided LIPITOR prescribing information.
Beetroot juice may lower blood pressure in some people.
Not addressed in the provided LIPITOR prescribing information.
If statin-related muscle injury happens, contact a clinician promptly.
Label text provided instructs clinicians to withhold/discontinue and discusses risk management, but the specific “contact a clinician promptly” phrasing is not supported verbatim or as an explicit instruction in the supplied label excerpts.
Adding strong juice regularly can sometimes change fluid/electrolyte balance depending on overall diet and health.
Not addressed in the provided LIPITOR prescribing information.
If you have low blood pressure or symptoms like dizziness or lightheadedness, you should be cautious with beetroot juice.
Not addressed in the provided LIPITOR prescribing information.
If you have kidney disease or a risk of dehydration, you should be cautious with beetroot juice.
While the label discusses rhabdomyolysis-related renal failure risk in the context of myopathy, it does not provide guidance regarding beetroot juice, dehydration, or kidney disease specifically in relation to beetroot juice.
Contradictions
Important Omissions
Drug interaction guidance specific to beetroot juice should not be assumed; the label specifically addresses grapefruit juice and strong CYP3A4 inhibitors, but beetroot juice is not mentioned.
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
Moderate
The response includes multiple unsupported claims about beetroot juice and related safety (blood pressure, dizziness/lightheadedness, dehydration/kidney disease). While it also correctly identifies key label-supported CYP3A4 metabolism and grapefruit interaction risk, the beetroot-specific safety assertions are not supported by the provided label text.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Medium |
Recommendation
Partially Aligned
Primary Issue
Beetroot juice interaction and safety statements are not supported by the supplied LIPITOR prescribing information.
Suggested Improvement
Remove or qualify beetroot juice-specific claims and rely on label-supported interaction information (e.g., grapefruit juice in Section 7.2 and CYP3A4 inhibitors in Section 7.1). Keep skeletal muscle guidance aligned to Section 5.1 (withhold/discontinue in myopathy/rhabdomyolysis risk contexts).